COGT

COGT

USD

Cogent Biosciences Inc. Common Stock

$14.130-1.110 (-7.283%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$15.240

Максимум

$15.870

Минимум

$13.980

Объем

0.44M

Фундаментальные показатели компании

Рыночная капитализация

2.0B

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

1.89M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $3.72Текущая $14.130Максимум $17.15

Связанные новости

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.

Просмотреть больше
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)

Просмотреть больше
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;

Просмотреть больше
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
GlobeNewswire

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today

Просмотреть больше
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Analyst Upgrades

JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44

JP Morgan analyst Anupam Rama maintains Cogent Biosciences with a Overweight and raises the price target from $30 to $44.

Просмотреть больше
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.